keyword
MENU ▼
Read by QxMD icon Read
search

Cognitive behavioral therapy app

keyword
https://www.readbyqxmd.com/read/28110674/evolution-of-cognitive-behavioral-therapy-for-eating-disorders
#1
W Stewart Agras, Ellen E Fitzsimmons-Craft, Denise E Wilfley
The evolution of cognitive-behavioral therapy (CBT) for the treatment of bulimic disorders is described in this review. The impacts of successive attempts to enhance CBT such as the addition of exposure and response prevention; the development of enhanced CBT; and broadening the treatment from bulimia nervosa to binge eating disorder are considered. In addition to developing advanced forms of CBT, shortening treatment to guided self-help was the first step in broadening access to treatment. The use of technology such as computer-based therapy and more recently the Internet, promises further broadening of access to self-help and to therapist guided treatment...
January 2017: Behaviour Research and Therapy
https://www.readbyqxmd.com/read/28031038/using-a-smartphone-app-to-reduce-cognitive-vulnerability-and-mild-depressive-symptoms-study-protocol-of-an-exploratory-randomized-controlled-trial
#2
Cezar Giosan, Cristina Mogoaşe, Oana Cobeanu, Aurora Szentágotai Tătar, Vlad Mureşan, Rareș Boian
BACKGROUND: Depression is a major challenge worldwide, with significant increasing personal, economic, and societal costs. Although empirically supported treatments have been developed, they are not always available for patients in routine clinical care. Therefore, we need effective and widely accessible strategies to prevent the onset of the very first depressive symptoms. Mental health apps could prove a valuable solution for this desideratum. Although preliminary research has indicated that such apps can be useful in treating depression, no study has attempted to test their utility in preventing depressive symptoms...
December 28, 2016: Trials
https://www.readbyqxmd.com/read/27964740/lw-afc-a-new-formula-derived-from-liuwei-dihuang-decoction-ameliorates-behavioral-and-pathological-deterioration-via-modulating-the-neuroendocrine-immune-system-in-prp-ha%C3%AE-ppswe-ps1-%C3%AE-e9-transgenic-mice
#3
Jian-Hui Wang, Xi Lei, Xiao-Rui Cheng, Xiao-Rui Zhang, Gang Liu, Jun-Ping Cheng, Yi-Ran Xu, Ju Zeng, Wen-Xia Zhou, Yong-Xiang Zhang
BACKGROUND: Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer's disease (AD). Notably, we previously revealed that the NIM network is dysregulated in the PrP-hAβPPswe/PS1(ΔE9) (APP/PS1) transgenic mouse model of AD. METHODS: After treatment with a novel Liuwei Dihuang formula (LW-AFC), mice were cognitively evaluated in behavioral experiments. Neuron loss, amyloid-β (Aβ) deposition, and Aβ level were analyzed using Nissl staining, immunofluorescence, and an AlphaLISA assay, respectively...
December 13, 2016: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/27852560/safety-acceptability-and-use-of-a-smartphone-app-blueice-for-young-people-who-self-harm-protocol-for-an-open-phase-i-trial
#4
Paul Stallard, Joanna Porter, Rebecca Grist
BACKGROUND: Up to 18% of adolescents will engage in an act of self-harm before young adulthood, with the majority of acts occurring in private. Mobile apps may offer a way of providing support for young people at times of distress to prevent self-harm. OBJECTIVE: This is a proof-of-concept study designed to explore the safety, acceptability, feasibility, and usability of a smartphone app, BlueIce, with young people who are self-harming. METHODS: In this phase I open trial we will evaluate BlueIce, a smartphone app developed and coproduced with young people with lived experience of self-harm...
November 16, 2016: JMIR Research Protocols
https://www.readbyqxmd.com/read/27833071/cognitive-behavior-therapy-for-anxious-and-depressed-youth-improving-homework-adherence-through-mobile-technology
#5
Pamela Wilansky, J Mikael Eklund, Tracy Milner, David Kreindler, Amy Cheung, Tim Kovacs, Shahin Shooshtari, Arlene Astell, Arto Ohinmaa, Joanna Henderson, John Strauss, Rosemary Sl Mills
BACKGROUND: Anxiety and mood disorders are the most common mental illnesses, peaking during adolescence and affecting approximately 25% of Canadians aged 14-17 years. If not successfully treated at this age, they often persist into adulthood, exerting a great social and economic toll. Given the long-term impact, finding ways to increase the success and cost-effectiveness of mental health care is a pressing need. Cognitive behavior therapy (CBT) is an evidence-based treatment for mood and anxiety disorders throughout the lifespan...
November 10, 2016: JMIR Research Protocols
https://www.readbyqxmd.com/read/27598869/preclinical-assessment-of-young-blood-plasma-for-alzheimer-disease
#6
Jinte Middeldorp, Benoit Lehallier, Saul A Villeda, Suzanne S M Miedema, Emily Evans, Eva Czirr, Hui Zhang, Jian Luo, Trisha Stan, Kira I Mosher, Eliezer Masliah, Tony Wyss-Coray
Importance: Alzheimer disease (AD) pathology starts long before clinical symptoms manifest, and there is no therapy to treat, delay, or prevent the disease. A shared blood circulation between 2 mice (aka parabiosis) or repeated injections of young blood plasma (plasma from 2- to 3-month-old mice) into old mice has revealed benefits of young plasma on synaptic function and behavior. However, to our knowledge, the potential benefit of young blood has not been tested in preclinical models of neurodegeneration or AD...
November 1, 2016: JAMA Neurology
https://www.readbyqxmd.com/read/27565118/an-internet-based-intervention-for-depression-in-primary-care-in-spain-a-randomized-controlled-trial
#7
Jesús Montero-Marín, Ricardo Araya, María C Pérez-Yus, Fermín Mayoral, Margalida Gili, Cristina Botella, Rosa Baños, Adoración Castro, Pablo Romero-Sanchiz, Yolanda López-Del-Hoyo, Raquel Nogueira-Arjona, Margarita Vives, Antoni Riera, Javier García-Campayo
BACKGROUND: Depression is the most prevalent cause of illness-induced disability worldwide. Face-to-face psychotherapeutic interventions for depression can be challenging, so there is a need for other alternatives that allow these interventions to be offered. One feasible alternative is Internet-based psychological interventions. This is the first randomized controlled trial (RCT) on the effectiveness of an Internet-based intervention on depression in primary health care in Spain. OBJECTIVE: Our aim was to compare the effectiveness of a low-intensity therapist-guided (LITG) Internet-based program and a completely self-guided (CSG) Internet-based program with improved treatment as usual (iTAU) care for depression...
August 26, 2016: Journal of Medical Internet Research
https://www.readbyqxmd.com/read/27435080/the-involvement-of-homocysteine-in-stress-induced-a%C3%AE-precursor-protein-misprocessing-and-related-cognitive-decline-in-rats
#8
Fang Xie, Yun Zhao, Jing Ma, Jing-Bo Gong, Shi-Da Wang, Liang Zhang, Xiu-Jie Gao, Ling-Jia Qian
Chronic stress is a risk factor in the development of cognitive decline and even Alzheimer's disease (AD), although its underlying mechanism is not fully understood. Our previous data demonstrated that the level of homocysteine (Hcy) was significantly elevated in the plasma of stressed animals, which suggests the possibility that Hcy is a link between stress and cognitive decline. To test this hypothesis, we compared the cognitive function, plasma concentrations of Hcy, and the brain beta-amyloid (Aβ) level between rats with or without chronic unexpected mild stress (CUMS)...
September 2016: Cell Stress & Chaperones
https://www.readbyqxmd.com/read/27354394/a-randomized-controlled-pilot-study-of-cbt-i-coach-feasibility-acceptability-and-potential-impact-of-a-mobile-phone-application-for-patients-in-cognitive-behavioral-therapy-for-insomnia
#9
Erin Koffel, Eric Kuhn, Napoleon Petsoulis, Christopher R Erbes, Samantha Anders, Julia E Hoffman, Josef I Ruzek, Melissa A Polusny
There has been growing interest in utilizing mobile phone applications (apps) to enhance traditional psychotherapy. Previous research has suggested that apps may facilitate patients' completion of cognitive behavioral therapy for insomnia (CBT-I) tasks and potentially increase adherence. This randomized clinical trial pilot study (n = 18) sought to examine the feasibility, acceptability, and potential impact on adherence and sleep outcomes related to CBT-I Coach use. All participants were engaged in CBT-I, with one group receiving the app as a supplement and one non-app group...
June 27, 2016: Health Informatics Journal
https://www.readbyqxmd.com/read/27135410/a-systematic-review-of-cognitive-behavioral-therapy-and-behavioral-activation-apps-for-depression
#10
Anna Huguet, Sanjay Rao, Patrick J McGrath, Lori Wozney, Mike Wheaton, Jill Conrod, Sharlene Rozario
Depression is a common mental health condition for which many mobile apps aim to provide support. This review aims to identify self-help apps available exclusively for people with depression and evaluate those that offer cognitive behavioural therapy (CBT) or behavioural activation (BA). One hundred and seventeen apps have been identified after searching both the scientific literature and the commercial market. 10.26% (n = 12) of these apps identified through our search offer support that seems to be consistent with evidence-based principles of CBT or BA...
2016: PloS One
https://www.readbyqxmd.com/read/27106171/development-of-a-wearable-cardiac-monitoring-system-for-behavioral-neurocardiac-training-a-usability-study
#11
Akib A Uddin, Plinio P Morita, Kevin Tallevi, Kevin Armour, John Li, Robert P Nolan, Joseph A Cafazzo
BACKGROUND: Elevated blood pressure is one of the main risk factors for death globally. Behavioral neurocardiac training (BNT) is a complementary approach to blood pressure and stress management that is intended to exercise the autonomic reflexes, improve stress recovery, and lower blood pressure. BNT involves cognitive-behavioral therapy with a paced breathing technique and heart rate variability biofeedback. BNT is limited to in-clinic delivery and faces an accessibility barrier because of the need for clinical oversight and the use of complex monitoring tools...
2016: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/27064434/adapting-evidence-based-cognitive-behavioral-interventions-for-anxiety-for-use-with-adults-in-integrated-primary-care-settings
#12
Robyn L Shepardson, Jennifer S Funderburk, Risa B Weisberg
Evidence-based treatments for adult patients with anxiety are greatly needed within primary care settings. Psychotherapy protocols, including those for cognitive-behavioral therapy (CBT), are often disorder-specific and were developed for specialty mental health settings, rendering them infeasible in primary care. Behavioral health consultants (BHCs) integrated into primary care settings are uniquely positioned to provide anxiety treatment. However, due to the dearth of empirically supported brief treatments for anxiety, BHCs are tasked with adapting existing treatments for use in primary care, which is quite challenging due to the abbreviated format and population-based approach to care...
June 2016: Families, Systems & Health: the Journal of Collaborative Family Healthcare
https://www.readbyqxmd.com/read/26972789/glucose-dependent-insulinotropic-polypeptide-ameliorates-mild-traumatic-brain-injury-induced-cognitive-and-sensorimotor-deficits-and-neuroinflammation-in-rats
#13
Yu-Wen Yu, Tsung-Hsun Hsieh, Kai-Yun Chen, John Chung-Che Wu, Barry J Hoffer, Nigel H Greig, Yazhou Li, Jing-Huei Lai, Cheng-Fu Chang, Jia-Wei Lin, Yu-Hsin Chen, Liang-Yo Yang, Yung-Hsiao Chiang
Mild traumatic brain injury (mTBI) is a major public health issue, representing 75-90% of all cases of TBI. In clinical settings, mTBI, which is defined as a Glascow Coma Scale (GCS) score of 13-15, can lead to various physical, cognitive, emotional, and psychological-related symptoms. To date, there are no pharmaceutical-based therapies to manage the development of the pathological deficits associated with mTBI. In this study, the neurotrophic and neuroprotective properties of glucose-dependent insulinotropic polypeptide (GIP), an incretin similar to glucagon-like peptide-1 (GLP-1), was investigated after its steady-state subcutaneous administration, focusing on behavior after mTBI in an in vivo animal model...
November 15, 2016: Journal of Neurotrauma
https://www.readbyqxmd.com/read/26972288/membrane-damage-induced-by-amyloid-beta-and-a-potential-link-with-neuroinflammation
#14
REVIEW
Eduardo J Fernandez-Perez, Christian Peters, Luis G Aguayo
It is well accepted that cortical and hippocampal synaptic densities are reduced in Alzheimer's disease (AD). These alterations in neuronal networking occur at the very onset of AD and may lead to the neuronal loss displayed in later stages of the disease, which is characterized by severe cognitive and behavioral impairments. Many studies suggest that amyloid-β (Aβ) oligomers are responsible for synaptic disconnections and neuronal death. The effects of Aβ in different brain regions are pleotropic, thus suggesting a common mechanism for toxicity...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/26888586/cbt-i-coach-a-description-and-clinician-perceptions-of-a-mobile-app-for-cognitive-behavioral-therapy-for-insomnia
#15
Eric Kuhn, Brandon J Weiss, Katherine L Taylor, Julia E Hoffman, Kelly M Ramsey, Rachel Manber, Philip Gehrman, Jill J Crowley, Josef I Ruzek, Mickey Trockel
STUDY OBJECTIVES: This paper describes CBT-I Coach, a patient-facing smartphone app designed to enhance cognitive behavioral therapy for insomnia (CBT-I). It presents findings of two surveys of U.S. Department of Veterans Affairs (VA) CBT-I trained clinicians regarding their perceptions of CBT-I Coach before it was released (n = 138) and use of it two years after it was released (n = 176). METHODS: VA-trained CBT-I clinicians completed web-based surveys before and two years after CBT-I Coach was publicly released...
April 15, 2016: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/26813737/moodhacker-mobile-web-app-with-email-for-adults-to-self-manage-mild-to-moderate-depression-randomized-controlled-trial
#16
Amelia J Birney, Rebecca Gunn, Jeremy K Russell, Dennis V Ary
BACKGROUND: Worldwide, depression is rated as the fourth leading cause of disease burden and is projected to be the second leading cause of disability by 2020. Annual depression-related costs in the United States are estimated at US $210.5 billion, with employers bearing over 50% of these costs in productivity loss, absenteeism, and disability. Because most adults with depression never receive treatment, there is a need to develop effective interventions that can be more widely disseminated through new channels, such as employee assistance programs (EAPs), and directly to individuals who will not seek face-to-face care...
January 26, 2016: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/26620558/systemic-central-nervous-system-cns-targeted-delivery-of-neuropeptide-y-npy-reduces-neurodegeneration-and-increases-neural-precursor-cell-proliferation-in-a-mouse-model-of-alzheimer-disease
#17
Brian Spencer, Rewati Potkar, Jeff Metcalf, Ivy Thrin, Anthony Adame, Edward Rockenstein, Eliezer Masliah
Neuropeptide Y (NPY) is one of the most abundant protein transmitters in the central nervous system with roles in a variety of biological functions including: food intake, cardiovascular regulation, cognition, seizure activity, circadian rhythms, and neurogenesis. Reduced NPY and NPY receptor expression is associated with numerous neurodegenerative disorders including Alzheimer disease (AD). To determine whether replacement of NPY could ameliorate some of the neurodegenerative and behavioral pathology associated with AD, we generated a lentiviral vector expressing NPY fused to a brain transport peptide (apoB) for widespread CNS delivery in an APP-transgenic (tg) mouse model of AD...
January 22, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/26538149/viral-gene-transfer-of-apps%C3%AE-rescues-synaptic-failure-in-an-alzheimer-s-disease-mouse-model
#18
Romain Fol, Jerome Braudeau, Susann Ludewig, Tobias Abel, Sascha W Weyer, Jan-Peter Roederer, Florian Brod, Mickael Audrain, Alexis-Pierre Bemelmans, Christian J Buchholz, Martin Korte, Nathalie Cartier, Ulrike C Müller
Alzheimer's disease (AD) is characterized by synaptic failure, dendritic and axonal atrophy, neuronal death and progressive loss of cognitive functions. It is commonly assumed that these deficits arise due to β-amyloid accumulation and plaque deposition. However, increasing evidence indicates that loss of physiological APP functions mediated predominantly by neurotrophic APPsα produced in the non-amyloidogenic α-secretase pathway may contribute to AD pathogenesis. Upregulation of APPsα production via induction of α-secretase might, however, be problematic as this may also affect substrates implicated in tumorigenesis...
February 2016: Acta Neuropathologica
https://www.readbyqxmd.com/read/26513023/a-smartphone-based-decision-support-tool-improves-test-performance-concerning-application-of-the-guidelines-for-managing-regional-anesthesia-in-the-patient-receiving-antithrombotic-or-thrombolytic-therapy
#19
RANDOMIZED CONTROLLED TRIAL
Matthew D McEvoy, William R Hand, Marjorie P Stiegler, Amy N DiLorenzo, Jesse M Ehrenfeld, Kenneth R Moran, Robert Lekowski, Mark E Nunnally, Erin L Manning, Yaping Shi, Matthew S Shotwell, Rajnish K Gupta, John M Corey, Randall M Schell
BACKGROUND: The American Society of Regional Anesthesia and Pain Medicine (ASRA) consensus statement on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy is the standard for evaluation and management of these patients. The authors hypothesized that an electronic decision support tool (eDST) would improve test performance compared with native physician behavior concerning the application of this guideline. METHODS: Anesthesiology trainees and faculty at 8 institutions participated in a prospective, randomized trial in which they completed a 20-question test involving clinical scenarios related to the ASRA guidelines...
January 2016: Anesthesiology
https://www.readbyqxmd.com/read/26475676/protein-structures-in-alzheimer-s-disease-the-basis-for-rationale-therapeutic-design
#20
REVIEW
Laia Montoliu-Gaya, Sandra Villegas
Alzheimer's disease (AD) is a neurodegenerative disorder that affects memory, behavior, thinking and emotion. Current therapies to treat AD patients are only capable for temporarily slowing-down the cognitive decline, as they are focused on ameliorating symptoms instead of targeting its underlying causes. The aim of this review is to describe what is known about the protein structures implicated in AD pathogenesis, amyloid cascade members, as well as those structures involved in Aβ clearance. Thus, structural information available for APP, α- β- and γ-secretases, CTFβ and derived Aβ peptides, AICDs, apoE and apoJ, LRP-1 and RAGE, and neprilysin and insulin-degrading enzyme is provided...
December 15, 2015: Archives of Biochemistry and Biophysics
keyword
keyword
69880
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"